Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher C A
Eijkman-Winkler Institute, Department of Virology, University Hospital Utrecht, The Netherlands.
AIDS. 1999 Dec 3;13(17):2349-59. doi: 10.1097/00002030-199912030-00006.
It is thought as a consequence of continuous replication, HIV-1 has acquired an optimal fitness state and that suboptimal antiretroviral therapy selects for drug resistant variants which show impaired fitness in the absence of the drug. In this paper we studied the evolution and fitness of viral populations appearing in a patient who received protease monotherapy.
Two factors contributing to fitness, drug resistance and protease catalytic activity, were studied at the enzymatic and virological level.
The first drug resistant viral variants that were selected in vivo harboured one to three protease substitutions. These mutants showed reduced protease activity and consequently a reduction in viral replication capacity. During continued in vivo replication of these viruses in the presence of the drug, novel variants harbouring additional substitutions in the viral protease appeared. These variants did not display any further increase in drug resistance but demonstrated clearly increased protease activity. Consequently the replication capacity of these viruses was raised to a level at which they replicated better than the original wild-type virus.
This study indicates that the viral population in the patient does not have to represent the fittest possible variants, and thus antiretroviral therapy may drive the viral population first through a lower fitness level and then to a higher fitness level.
人们认为,由于持续复制,HIV-1已达到最佳适应状态,而次优抗逆转录病毒疗法会选择出耐药变异体,这些变异体在无药物情况下显示出适应性受损。在本文中,我们研究了接受蛋白酶单一疗法的一名患者体内出现的病毒群体的进化和适应性。
在酶学和病毒学水平上研究了影响适应性的两个因素,即耐药性和蛋白酶催化活性。
在体内选择出的首批耐药病毒变异体含有一至三个蛋白酶替代位点。这些突变体显示蛋白酶活性降低,因而病毒复制能力下降。在药物存在的情况下,这些病毒在体内持续复制期间,出现了在病毒蛋白酶中含有额外替代位点的新变异体。这些变异体的耐药性没有进一步增强,但蛋白酶活性明显提高。因此,这些病毒的复制能力提高到了比原始野生型病毒更好的复制水平。
本研究表明,患者体内的病毒群体不一定代表可能的最适应变异体,因此抗逆转录病毒疗法可能先使病毒群体经历较低的适应水平,然后再达到较高的适应水平。